US Corporate Distress Financial Stress SEC Filings — April 15, 2026

15-04-2026

Spire Inc. entered into a definitive agreement to sell its natural gas storage assets (Spire Storage in Wyoming and Oklahoma) to I Squared Capital for $650 million ($600 million cash at closing plus $50 million deferred payment in FY2027), sharpening focus on regulated utility businesses and improving risk profile while funding the recent Piedmont Natural Gas Tennessee acquisition. The transaction supports system reliability under new ownership and is expected to close in the second half of FY2026, subject to customary conditions and HSR antitrust review. Spire affirmed FY2026 adjusted EPS guidance of $5.25–$5.45 and FY2027 guidance of $5.40–$5.60, reaffirming 5-7% long-term EPS growth from the original FY2027 midpoint of $5.75.

• ·Spire Storage West located in southwestern Wyoming, serves western U.S.; Salt Plains in north central Oklahoma, connected to Southern Star Pipeline and Oklahoma Gas Transmission, serves midcontinent and midwestern U.S.
• ·Transaction subject to customary closing conditions and HSR antitrust waiting period expiration/termination.
• ·Sale of Spire Marketing expected to close in Q3 FY2026; both sales subject to regulatory approvals.
• ·Greenhill (Mizuho affiliate) as Spire's exclusive financial advisor; Vinson & Elkins as Spire legal counsel; Kirkland & Ellis as I Squared legal advisor.
• ·Revised 2026 guidance to be provided on Q2 FY2026 earnings call in May 2026.
• ·Piedmont Natural Gas Tennessee acquisition closed March 31, 2026.

15-04-2026

Marvell Technology, Inc. completed a public offering of $1,000,000,000 aggregate principal amount of its 5.300% Senior Notes due 2036 on April 15, 2026, governed by the Fifth Supplemental Indenture with U.S. Bank Trust Company, National Association. Net proceeds of approximately $993.5 million, after underwriters' discount but before other expenses, will be used for repayment of debt including the Company's 1.650% senior notes due 2026, and general corporate purposes such as working capital, dividends, capital expenditures, stock repurchases, and acquisitions. The notes accrue interest at 5.300% per year, payable semi-annually starting October 15, 2026, and mature on April 15, 2036.

• ·Underwriting Agreement dated April 6, 2026, among the Company and representatives Wells Fargo Securities, LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC.
• ·Prior to par call date of January 15, 2036, Notes redeemable at greater of discounted value using Treasury Rate plus 15 basis points or 100% principal.
• ·Offered pursuant to shelf registration statement on Form S-3 (No. 333-285742) filed March 12, 2025.

15-04-2026

Strawberry Fields REIT, Inc. disclosed various risk factors in an 8-K filing, highlighting heavy concentration risks with 86.8% of annualized base rent from 15 master leases affiliated with executives Moishe Gubin and Michael Blisko, and 97.7% derived from skilled nursing facilities. The company also faces substantial indebtedness of $752.1 million as of December 31, 2025, along with vulnerabilities from related-party leases not negotiated at arm's length, potential tenant defaults, labor shortages, inflation, and dependence on key personnel. These factors could materially adversely affect operations, financial condition, and distributions to stockholders.

• ·Leases with related parties not negotiated on arm’s-length basis and subject to conflicts of interest policies requiring audit committee approval.
• ·Tenants under master leases are affiliates, increasing risk of widespread defaults from single adverse events like regulatory exclusions from Medicare/Medicaid.
• ·Portfolio lacks diversification, with tenant base limited to skilled nursing operators dependent on government reimbursements.

15-04-2026

On April 10, 2026, Soluna Holdings, Inc. received a notice from Nasdaq indicating that its common stock (SLNH) closing bid price was below $1.00 per share for 30 consecutive business days, resulting in non-compliance with Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until October 7, 2026, to regain compliance by maintaining a $1.00+ closing bid for 10 consecutive business days, with no immediate effect on trading. The company intends to monitor the stock price and consider strategies to achieve compliance, potentially qualifying for a second 180-day period if needed.

• ·Nasdaq Listing Rule 5810(c)(3)(A) governs the 180-day compliance period.
• ·If non-compliant after initial and potential second periods, Nasdaq will notify of delisting determination, with option to appeal to a Nasdaq Hearings Panel.
• ·Notice applies only to common stock (SLNH); preferred stock (SLNHP) unaffected.
• ·Company address: 325 Washington Avenue Extension, Albany, New York 12205.

15-04-2026

Leidos Holdings, Inc. (NYSE: LDOS) and investment firm Altaris have formed a U.S.-based joint venture by combining Leidos' Security Enterprise Solutions (SES) business, contributing approximately 1,500 employees and $625 million in projected 2026 revenue, with Altaris-owned Analogic to enhance global security screening capabilities for airports, borders, and critical infrastructure. The JV will operate under the Analogic brand with Leidos retaining significant minority ownership, aiming to drive innovation in AI-native and 3D imaging solutions while allowing Leidos to focus on core growth areas in its NorthStar 2030 strategy. The transaction is expected to close in the second half of 2026, subject to regulatory approvals and customary conditions.

• ·Leidos headquartered in Reston, Virginia; Analogic in Salem, NH; Altaris in New York City.
• ·Advisors: Leidos - PJT Partners (financial), Fried Frank Harris Shriver & Jacobson LLP and DLA Piper (legal), KPMG (accounting); Analogic - Kirkland & Ellis LLP and Hinckley Allen & Snyder LLP (legal), Ernst & Young LLP (accounting).

15-04-2026

Allbirds, Inc. entered into Support Agreements on April 8, 2026, with stockholders holding approximately 71% of voting power (as of February 28, 2026) to vote in favor of the previously announced Asset Sale to Allbirds IP LLC, affiliated with American Exchange Group, as recommended by the Board at an upcoming Special Meeting. The supporting stockholders include Maveron (a >5% holder of Class B common stock) and board members Joey Zwillinger, Tim Brown, and Dick Boyce. The company intends to file a Proxy Statement with the SEC and notes risks to consummation, including stockholder approval and closing conditions.

• ·Asset Purchase Agreement originally entered on March 29, 2026
• ·Proxy Statement to be filed with SEC in connection with Special Meeting
• ·8-K filed on April 15, 2026; event date April 8, 2026

15-04-2026

Aspire Biopharma Holdings, Inc. entered into a non-binding letter of intent (LOI) on April 15, 2026, to acquire 100% of the Driver Controls Systems (DCS) business unit of Firefish Topco, LLC for an enterprise value of $30.0 million on a cash-free, debt-free basis, payable in cash at closing subject to customary adjustments. The LOI includes $3.5 million break-up fees, a 30-day exclusivity period with no-shop provisions, and plans to engage Lakewood & Company, LLC for post-acquisition management services. Completion remains subject to definitive agreements and conditions, with no new equity raise anticipated.

• ·LOI is non-binding except for exclusivity, confidentiality, expenses, and break-up fees post-disclosure.
• ·Purchase not subject to working capital adjustment if operated in ordinary course.
• ·Lakewood & Company principals have more than 100 years of automotive industry experience.

15-04-2026

Stereotaxis, Inc. filed an 8-K on April 15, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), Regulation FD disclosure (Item 7.01), and financial statements and exhibits (Item 9.01). No specific financial metrics or period-over-period comparisons are detailed in the filing metadata. The filing size is 3 MB, indicating potential exhibits or press releases attached.

• ·CIK: 0001289340
• ·SIC: 3845 (Electromedical & Electrotherapeutic Apparatus)
• ·Business Address: 710 N Tucker Blvd Ste 110, St. Louis, MO 63101
• ·Fiscal Year End: December 31

15-04-2026

Graham Corporation (NYSE: GHM) announced a $50 million investment from accounts advised by T. Rowe Price Investment Management, Inc., involving the sale of 599,808 shares (5% of common stock) at $83.36 per share, based on the 20-day average closing price as of April 13, 2026. The transaction is expected to close on April 16, 2026, subject to customary conditions, with proceeds intended for debt repayment to strengthen the balance sheet and funding organic and inorganic growth opportunities. CEO Matthew J. Malone highlighted the investment as validation of the company's platform and support for long-term shareholder value.

• ·Transaction expected to close on April 16, 2026, subject to customary closing conditions
• ·Stock purchase agreement includes registration statement to be filed with SEC within 30 days
• ·Proceeds to enhance financial flexibility for debt repayment and growth investments

15-04-2026

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that its board of directors unanimously approved a plan to redomicile the parent company from Singapore to the United States as a new Delaware corporation, Wave Life Sciences, Inc., via a one-for-one exchange of ordinary shares for common stock. The move aims to streamline organizational structure, enhance administrative efficiencies, and reduce dual financial reporting and compliance costs, with the company continuing to trade on Nasdaq under 'WVE' and report under U.S. GAAP. Subject to shareholder approval and Singapore High Court sanction, the redomiciliation is expected to take effect in mid-2026 and be tax-free for U.S. shareholders.

• ·Preliminary proxy materials filed with SEC on April 15, 2026, in preparation for shareholder meeting.
• ·Proxy statement for 2025 Annual Meeting of Shareholders filed with SEC on June 23, 2025.
• ·Headquartered in Cambridge, MA.

15-04-2026

LQR House Inc. entered into a Share Purchase Agreement on April 11, 2026, to acquire all 10,000 ordinary shares of Fusion Five Continents Securities Limited, a New Zealand brokerage enabling stablecoin deposits for trading Hong Kong and U.S. equities, for a total of $126,880,000 payable in USDT, with an initial closing of 24% (2,400 shares) for $28,080,000 no later than April 24, 2026, and the remaining 76% (7,600 shares) for $98,800,000 after regulatory approvals. In connection with the acquisition, the Board appointed Yuting “Tina” Luo (to Audit and Nominating Committees) and Hoi Ho George Wong (to Compensation Committee) as independent directors on April 10, 2026, each entitled to $48,000 annual cash fees. No financial performance metrics or declines were reported.

• ·Initial closing required no later than April 24, 2026.
• ·Second closing(s) after 10 business days following satisfaction of conditions including regulatory approvals.
• ·Payments to be made in Tether (USDT) to seller-designated wallet.
• ·New directors appointed April 10, 2026, with standard indemnification agreements and $48,000 annual fees payable monthly.

15-04-2026

Harvard Apparatus Regenerative Technology, Inc. issued a $300,000 bridge note to Junli He on April 13, 2026, bearing 8% annual interest and maturing on the earlier of a capital raise of at least $5,000,000 or April 13, 2027. The note allows optional conversion into equity securities upon a qualified financing of at least $300,000 at the financing price. No period-over-period financial metrics are provided, but the issuance signals short-term liquidity needs ahead of larger fundraising.

• ·Prepayment allowed at any time without penalty or premium.
• ·Governed by laws of Massachusetts; parties waive jury trial.
• ·Events of default include Act of Bankruptcy, Sale of the Company, or failure to pay judgments over $100,000.

15-04-2026

Eton Pharmaceuticals, Inc. entered into the Sixth Amendment to its Credit Agreement, originally dated November 13, 2019, with SWK Funding LLC as agent and sole lender, effective April 9, 2026. The amendment updates Annex I to confirm SWK Funding LLC's $40,000,000 term loan commitment at 100% pro rata share. Effectiveness is conditioned on the consummation of mergers under the October 9, 2025 Agreement and Plan of Merger involving Runway Growth Finance Corp. and SWK Holdings Corporation, with no changes to financial performance metrics disclosed.

• ·Amendment filed as 8-K on April 15, 2026, covering Items 1.01, 2.03, and 9.01
• ·Conditions precedent include payment of Agent’s and Runway’s outside counsel fees, true and correct representations/warranties, and no Default or Event of Default
• ·No waiver of any past, present, or future non-compliance under the Credit Agreement

15-04-2026

On April 9, 2026, Trinity Industries Leasing Company (TILC), a wholly-owned subsidiary of Trinity Industries, Inc., entered into a Contribution Agreement, contributing its 42.56% membership interest in TRIP Rail Holdings LLC and 0.2% interest in Triumph Rail Holdings LLC to NP SPE Holdings LP in exchange for a 11.2% limited partnership interest in NP SPE. As a result, TILC no longer holds any direct ownership in TRIP Holdings or Triumph Holdings, and these entities will no longer be consolidated in Trinity's financial statements. The Contribution Agreement is filed as Exhibit 10.1.

• ·Filing date: April 15, 2026
• ·Date of earliest event reported: April 9, 2026

15-04-2026

Flowserve Corporation entered into a Third Amended and Restated Credit Agreement dated April 15, 2026, providing $1,450,000,000 in senior credit facilities, including a $1,000,000,000 revolving credit facility and an implied $450,000,000 term loan facility. Bank of America, N.A. serves as Administrative Agent, Swing Line Lender, and L/C Issuer, with other major banks as Co-Syndication Agents and Co-Documentation Agents. The agreement includes an Alternative Currency Sublimit of $350,000,000 within the revolving commitments.

15-04-2026

Federal Realty OP LP entered into a Third Amended and Restated Credit Agreement dated April 14, 2026, amending and restating its prior agreement from October 5, 2022, to provide an unsecured revolving credit facility of $1,400,000,000, including a $100,000,000 swingline subfacility and a $50,000,000 letter of credit subfacility. The agreement involves multiple lenders led by Wells Fargo Bank, National Association as Administrative Agent, with PNC Capital Markets LLC as Sustainability Structuring Agent. No performance metrics or changes from prior facility size are disclosed.

• ·Loan Number: 1004039
• ·Prior agreement dated October 5, 2022

15-04-2026

On April 9, 2026, Hyundai Capital America (Sponsor), Hyundai ABS Funding, LLC (Depositor), Hyundai Auto Receivables Trust 2022-A (Issuing Entity), Citibank, N.A. (Indenture Trustee), and U.S. Bank Trust National Association (Owner Trustee) entered into an Omnibus Distribution and Termination Agreement, with the consent of owners holding 100% of the outstanding certificates and all classes of notes. The agreement, attached as Exhibit 10.1, signals the wind-down of the trust. The 8-K was filed on April 15, 2026.

• ·Central Index Key Numbers: Hyundai Auto Receivables Trust 2022-A (0001913196), Hyundai ABS Funding, LLC (0001260125), Hyundai Capital America (0001541028)

15-04-2026

U.S. Physical Therapy, Inc. entered into a Fourth Amended and Restated Credit Agreement on April 14, 2026, amending and restating the Third Amended and Restated Credit Agreement dated June 17, 2022, to provide a modified revolving credit facility and term loan facility. Bank of America, N.A. serves as Administrative Agent, Swingline Lender, and L/C Issuer, with other banks including Regions Capital Markets as Syndication Agent and Citizens Bank, N.A., JPMorgan Chase Bank, N.A., and U.S. Bank National Association as Co-Documentation Agents. The agreement constitutes an extension and renewal of prior indebtedness without extinguishment.

• ·CUSIP Numbers: Published 90355KAD9, Revolver 90355KAE7, Term Loan 90355KAF4.
• ·Applicable Rate grid has 5 pricing levels based on Consolidated Leverage Ratio from <1.25:1.0 (Level 1: Term SOFR/LC Fee 1.250%, Base Rate 0.250%, Commitment Fee 0.225%) to ≥3.25:1.0 (Level 5: 2.250%, 1.250%, 0.350%).
• ·SEC 8-K filed April 15, 2026, Items 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits).

15-04-2026

Marchex, Inc. entered into a Settlement Agreement on April 14, 2026, resolving the civil action Chris Barnard and Sinc McEvenue v. Marchex, Inc. (C.A. No. 1:22-cv-01382-RGA) in the U.S. District Court for the District of Delaware, for the expected settlement amount previously accrued in its 2025 Form 10-K. Pursuant to the agreement, the company will pay $750,000 (and release $250,000 held in escrow by U.S. Bank) on or before May 14, 2026, followed by $500,000 payments on November 16, 2026, and May 17, 2027.

• ·Settlement resolves all claims in the matter; full agreement text to be filed as an exhibit in next periodic report or registration statement.
• ·Further details in Note 10 to Consolidated Financial Statements and Item 3. Legal Proceedings of the 2025 Form 10-K.

15-04-2026

Empire State Realty OP, L.P. (the 'Company') and Empire State Realty Trust, Inc. (the 'Parent') entered into a Note Purchase Agreement dated April 15, 2026, for the issuance and sale of $130,000,000 aggregate principal amount of 5.99% Series M Senior Notes due July 15, 2032. The closing is scheduled for July 15, 2026, at the offices of Morgan, Lewis & Bockius LLP in New York, subject to customary conditions including representations, warranties, and no material adverse effect. No period-over-period financial comparisons or performance metrics are provided in the filing.

• ·Closing to occur not later than 1:00 p.m. New York time on July 15, 2026, or such later business day as mutually agreed.
• ·Notes to be purchased at 100% of principal amount; minimum denominations of $100,000.
• ·No transactions prohibited by Section 10 covenants since December 31, 2025, as a condition to closing.

15-04-2026

Integra LifeSciences Holdings Corporation amended its $150 million accounts receivable securitization facility (A/R Facility) through Amendment No. 8 to the Receivables Financing Agreement and Amendment No. 1 to the Purchase and Sale Agreement on April 10, 2026. The amendments extend the scheduled termination date to April 10, 2029, and update customary representations, covenants, and concentration limits on receivables. This provides continued liquidity and funding support for the company's operations.

• ·Original A/R Facility entered into on December 18, 2018.
• ·Amendments to be filed as exhibits to Form 10-Q for period ended March 31, 2026.

15-04-2026

Limoneira Company announced the completion of definitive agreements for a 50%/50% joint venture with Agromin to develop a 70-acre commercial composting center on its Santa Paula property, expanding from an existing 15-acre operation to process approximately 295,000 tons of organic waste annually, with operations expected in the second half of fiscal year 2027. The facility will generate revenue from gate fees and compost sales, sharing significant EBITDA equally between partners, while Limoneira will lease the site for approximately $560,000 annually including 89-acre feet of water. This initiative supports California's Senate Bill 1383 organic waste diversion mandates, positioning the center as the only permitted commercial composting facility in Ventura County, expected to divert 75% of the county's landfilled organic waste.

• ·Joint venture follows letter of intent announced in April 2025.
• ·15 years of planning and permitting required for food waste processing.
• ·Limoneira headquartered in Santa Paula, California, with operations in California, Arizona, and Argentina.
• ·Agromin headquartered in Oxnard, California, and is a U.S. Composting Council Composter of the Year recipient.

15-04-2026

On April 13, 2026, iShares Staked Ethereum Trust ETF (ETHB) entered into an amended and restated addendum to the Coinbase Custody Custodial Services Agreement, which is attached to the Third Amended and Restated Coinbase Prime Broker Agreement dated May 21, 2024. The addendum is filed as Exhibit 10.1. No financial impacts or performance metrics are disclosed in the filing.

• ·Filing submitted on behalf of iShares Delaware Trust Sponsor LLC, the Sponsor of the Trust.
• ·Schedules and exhibits to Exhibit 10.1 omitted pursuant to Item 601(a)(5) of Regulation S-K; available supplementally to SEC upon request.

15-04-2026

Owens Corning amended the sale agreement for its global glass reinforcements (GR) business, reducing the enterprise value from $755 million to $645 million and recognizing an additional $140 million impairment loss due to the lower purchase price and other adjustments. The company received a $30 million non-refundable deposit from the buyers and expects approximately $280 million in after-tax net proceeds upon closing in Q2 2026, to be used for growth investments and shareholder returns. While the impairment represents a significant loss, the transaction is proceeding with secured deposit.

• ·GR Business classified as held for sale and results reflected as discontinued operations beginning with Q1 2025 10-Q (period ended March 31, 2025).
• ·Original definitive agreement dated February 13, 2025; initial impairment disclosure on February 14, 2025.
• ·Amendment executed on April 14, 2026 due to changing market conditions; eliminates promissory notes from buyers.

15-04-2026

On April 9, 2026, Alaunos Therapeutics, Inc. received a notice from Nasdaq for failing to comply with Listing Rule 5550(b)(1), as its FY 2025 10-K reported stockholders’ equity of $2,153,000, below the $2,500,000 minimum; it also fails alternative standards of $35 million market value of listed securities or $500,000 net income. The company has until May 26, 2026, to submit a compliance plan, which may grant up to 180 days extension if accepted, and intends to evaluate actions to regain compliance. There is no assurance of acceptance or regaining compliance, potentially leading to delisting.

• ·Nasdaq will evaluate compliance plan based on factors including ability to sustain 12 months of equity compliance, past history, reasons for non-compliance, other events, financial condition, and disclosures.
• ·If plan rejected or compliance not regained, company can request hearing before Nasdaq panel, staying any delisting.
• ·Trading expected to continue post-disclosure to Nasdaq’s MarketWatch.

15-04-2026

Ecolab Inc. entered into a Term Credit Agreement dated April 10, 2026, acting as Borrower, with financial institutions as Lenders and Citibank, N.A. as Administrative Agent, Sole Arranger, and Sole Bookrunner. The agreement outlines terms for term loans, including interest rates based on SOFR benchmarks with applicable margins, repayment schedules, covenants, and events of default. No specific commitment amounts, loan sizes, or numerical financial terms are detailed in the provided filing excerpt.

• ·Filing Date: April 15, 2026
• ·SEC Items: 1.01 (Entry into Material Definitive Agreement), 2.03 (Creation of Direct Financial Obligation), 9.01 (Financial Statements and Exhibits)
• ·Interest rate floors: Base Rate not less than 1.00%; Adjusted Daily Simple SOFR and Adjusted Term SOFR not less than zero

15-04-2026

BioCardia, Inc. received a Nasdaq notice on April 10, 2026, indicating non-compliance with the minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1), as its equity stood at $895,000 as of December 31, 2025. The company has until May 25, 2026, to submit a plan to regain compliance, potentially earning a 180-day extension, but faces risks of delisting if unsuccessful. Trading of common stock (BCDA) continues unaffected for now.

• ·Common Stock: par value $0.001, trading symbol BCDA on The Nasdaq Capital Market
• ·Potential extension: up to 180 calendar days from April 10, 2026, if compliance plan accepted

15-04-2026

Mitesco, Inc. announced the release of a video highlighting Sportzfolio, its strategic partner platform—a digital marketplace for sports facilities initially focused on pickleball, with plans to expand to soccer, tennis, golf, and basketball. The platform is developed via Vero Technology Ventures and hosted on Mitesco's Centcore Data Center, with a revenue sharing arrangement aligning long-term interests. This milestone supports upcoming pilot programs, sponsorships, and market rollout ahead of MVP launch.

• ·Video available at: https://www.youtube.com/watch?v=x2rDJtDiiLo
• ·Filing Date: April 15, 2026; Announcement Date: April 09, 2026

15-04-2026

On April 15, 2026, PAR Technology Corporation entered into a Board Observer Agreement with Voss Capital entities, appointing Jon Hook as a non-voting observer to the Board of Directors. The observer receives meeting materials and can attend meetings subject to exceptions for confidentiality and conflicts, with the agreement lasting one year and terminable under specified conditions including ownership thresholds. No fees are involved, only potential expense reimbursement for in-person attendance.

• ·Observer has no voting rights or fiduciary duties
• ·Termination triggers include uncured material breach, seeking board representation, or Voss Capital falling below minimum ownership threshold
• ·Agreement includes confidentiality and non-disparagement provisions

15-04-2026

Visium Technologies, Inc. executed a Settlement Agreement dated April 10, 2026, eliminating approximately $182,243.75 in outstanding Labrys Notes and 5,112,426 Talos Warrants, removing all conversion rights, derivative liabilities, and potential dilution. The settlement provides a discount of more than 18% below the face amount of the notes via a single payment due on or before April 13, 2026. This action strengthens the capital structure ahead of the Letter of Intent to acquire ConnexUs AI.

• ·Settlement payment due on or before April 13, 2026
• ·Agreement includes mutual general releases and termination of share reserves and transfer agent instructions
• ·Company headquartered at 4094 Majestic Lane, Suite 360, Fairfax, VA 22033

15-04-2026

Mainz Biomed N.V. entered into an asset purchase agreement on April 9, 2026, to sell its Next Gen IP (intellectual property for next-generation colorectal cancer screening products) to an Italian third-party buyer for $1.25 million, with closing targeted by April 23, 2026, following the prior wind-down of its ColoAlert product and sale of its IP on March 28, 2026, to pivot focus to pancreatic cancer screening and post-quantum cybersecurity. In Item 8.01, the company reports that after receiving $6 million in equity investments ($3 million on February 13, 2026, and $3 million pre-payment in March 2026), it believes stockholders' equity now exceeds Nasdaq's $2.5 million minimum, improving from $641,600 as of December 31, 2025; however, the product wind-down reflects a strategic shift away from prior colorectal cancer efforts.

• ·Sale closing contingent on third-party consents/acknowledgements, shipment of samples/materials, and patent application deadline extensions.
• ·Net proceeds from Next Gen IP sale to be used for settling outstanding liabilities and general corporate purposes.
• ·Company trading symbol: QUCY on Nasdaq Capital Market.
• ·Wind-down decision and terminations occurred prior to February 2026.

15-04-2026

Traws Pharma announced a PIPE financing expected to provide $10.0 million in upfront gross proceeds, led by Sirenia Capital Management, with up to $50 million additional from milestone-based (Series A and B warrants totaling $20 million) and three-year Series C warrants ($30 million), positioning the company to fund a UK human challenge trial for tivoxavir marboxil. The financing was priced at-the-market at $1.6730 per share. However, forward-looking statements highlight risks including a current FDA clinical hold on the tivoxavir marboxil IND filing.

• ·PIPE priced at $1.6730 per share with exercise price equal to deal price for warrants
• ·Financing completed April 15, 2026, with funding expected April 16, 2026, subject to customary closing conditions
• ·Company to file SEC registration statement for resale of shares underlying the securities
• ·Seeking development and commercialization partners for legacy oncology programs rigosertib and narazaciclib

15-04-2026

On April 10, 2026, Totaligent, Inc. entered into a Definitive Agreement with Ivan Klarich to acquire Aetherium Medical's team, business plan, trade secrets, know-how, network contacts, and operational infrastructure (Aetherium Assets) in exchange for milestone-based equity, including an initial 10% fully-diluted equity issuance upon closing. Klarich will be appointed President immediately and join the Board post-closing, with the Board expanding to three members. Closing is scheduled 30 days after the effective date, subject to customary conditions like employment agreements.

• ·Series D Preferred Stock convertible into 1,000 shares of Common Stock or Common Stock equivalent.
• ·Milestones include joint-venture formation, strategic partnerships, revenue run-rate targets, Don Heath-related transaction, and uplist/qualified IPO true-up.
• ·Aetherium Assets consist primarily of trade secrets, know-how, business relationships, and distribution rights with no registered patents, trademarks, or third-party liabilities.

15-04-2026

Tilray Brands, Inc. acquired the Lyphe Group, a leading UK medical cannabis clinic and digital pharmacy with approximately 150,000 units dispensed and over 16,000 patients treated, to expand its vertically integrated UK healthcare platform, expected to be accretive in 2027. The company is stabilizing BrewDog six weeks post-acquisition, targeting cash flow positivity in 2027 and rebuilding toward a prior valuation of over $1 billion through investments in innovation and brewpubs. Tilray filed a $180 million ATM equity program to support global beverage expansion and is positioning for U.S. medical cannabis opportunities upon rescheduling.

• ·Tilray supports over 40 brands in over 20 countries.
• ·Lyphe acquisition creates first fully vertically integrated patient-centric medical platform combining cultivation, clinical care, dispensing, and distribution.
• ·ATM program managed by Jefferies LLC, TD Securities (USA) LLC, and Roth Capital Partners, LLC under Form S-3 (File No. 333-267788).

15-04-2026

Transglobal Management Group, Inc. entered into a Purchase Agreement dated April 1, 2026, and an Amendment dated April 10, 2026, to acquire substantially all assets of the Apache Creek Golf Course business from Dalston LLP for a total purchase price of $2,500,000, including a $200,000 deposit already paid, $300,000 cash due by April 30, 2026, and $2,000,000 by June 30, 2026. Ownership and possession transferred upon the deposit payment, enabling the Company to operate the business as a going concern under existing leasehold interests held by the Seller. However, failure to meet remaining payment deadlines allows the Seller to retain the deposit and revert ownership.

• ·Agreements include customary representations, warranties, covenants, and indemnification provisions.
• ·Full text of Purchase Agreement (Exhibit 10.1) and Amendment (Exhibit 10.2) filed with the 8-K.

15-04-2026

SUNation Energy, Inc. announced Board approval for the partial conversion of approximately $1.2 million of long-term debt into 677,000 shares of restricted common stock at $1.77 per share, a 10% premium to the April 13, 2026 closing price, reducing leverage and eliminating near-term cash obligations through September 2026. The shares represent 19.9% of the outstanding public float and are subject to a 180-day lock-up. This follows the elimination of $14 million in other short- and long-term debt over the past 14 months amid an ongoing strategic review.

• ·Debt under April 2025 (originally November 2022) senior secured promissory note held by CEO and CFO
• ·Transaction subject to final documentation and customary closing conditions
• ·Ongoing strategic review announced April 9, 2026; no further updates unless Board approves specific action

15-04-2026

FreeCast, Inc. approved the issuance of 137 warrants to 137 accredited investors on April 1, 2026, allowing the purchase of an aggregate 6,743,587 shares of Class A common stock at an exercise price of $4.25 per share, with the warrants issued on April 8, 2026, and enforceable from April 10, 2026, expiring May 15, 2026. The warrants are cash-exercisable only, immediately exercisable, and exempt from registration under Section 4(a)(2) and Rule 506 of Regulation D. No exercises have occurred as of the filing date of April 15, 2026.

• ·Warrants approved by board on April 1, 2026; exercise price set at Nasdaq closing price on that date.
• ·Warrants not enforceable until signed and delivered on April 10, 2026; replace prior warrants expired December 31, 2025.
• ·No cashless exercise permitted; expire 5:00 p.m. EST on May 15, 2026.

15-04-2026

First Mid Bancshares, Inc. entered into a Business Loan Agreement with Bankers' Bank on April 10, 2026, establishing a revolving line of credit secured by a Negative Pledge and Negative Assignment Agreement on 100% of the issued and outstanding capital stock of First Mid Bank & Trust, National Association. Advances can be requested orally or in writing by authorized persons Mike Taylor, Aaron Holt, or Jordan Read, subject to conditions precedent including provision of loan documents, resolutions, and no events of default. The agreement remains effective until all indebtedness is paid in full, with standard representations, warranties, and covenants including maintenance of financial records per GAAP and insurance.

• ·Agreement effective as of April 10, 2026
• ·Borrower organized under Delaware laws, principal office at 1421 Charleston Avenue, Mattoon, IL 61938
• ·Lender address: 700 Mineral Point Road, Madison, WI 53717
• ·Advance requests received after 3:00 PM Central Standard Time processed next business day

15-04-2026

Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) entered into a confirmatory Intellectual Property Assignment Agreement on April 9, 2026, with CEO Naveen Kulkarni, assigning all rights to U.S. Patent Application Publication No. US20250146029A1 for 'Modified Polypeptides for Enzymatic Synthesis of Ibuprofen,' filed November 2, 2023, and published May 8, 2025. This formalizes IP rights previously acquired under an Asset Purchase Agreement dated February 21, 2023, effective as of the patent filing date. The company is amending its Form 10-K for FY ended July 31, 2025, and 10-Qs for periods ended October 31, 2025, and January 31, 2026, to update related disclosures.

• ·Patent Application: US20250146029A1, filed November 2, 2023, published May 8, 2025
• ·Assignment effective as of November 2, 2023
• ·Exhibit 10.1: Intellectual Property Assignment Agreement dated April 9, 2026